Alvotech Form 20-F Summary: Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Company: Alvotech (Luxembourg public limited company)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Alvotech is a vertically integrated biotechnology company focused on developing and manufacturing biosimilar medicines. The company operates a purpose-built facility in Reykjavik, Iceland, and relies on a global network of commercial partners (including Teva, STADA, Advanz Pharma, and Fuji Pharma) for distribution. As of year-end 2025, Alvotech had five approved biosimilars (AVT02, AVT04, AVT03, AVT05, AVT06) and a pipeline of approximately 30 candidates.
Key Financial Metrics
| Metric (USD in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $586.3 | $489.7 |
| Product Revenue | $276.3 | $273.5 |
| License and Other Revenue | $310.1 | $216.2 |
| Net Profit / (Loss) | $27.9 | $(231.9) |
| Adjusted EBITDA | $137.2 | $108.3 |
| Cash and Cash Equivalents | $172.4 | $51.4 |
| Total Debt Outstanding | $1,299.1 | $1,068.6 |
| Operating Cash Flow | $(50.2) Used | $(236.8) Used |
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net profit of $27.9 million in 2025, a significant improvement from a net loss of $231.9 million in 2024. This was driven by a $93.8 million increase in license and other revenue (due to regulatory milestones) and a reduction in finance costs.
- Revenue Growth: Total revenue increased 20% year-over-year. License revenue grew 43.4%, primarily from milestones for AVT03, AVT05, AVT06, and pipeline programs. Product revenue remained relatively flat (+1.0%) as pre-launch shipments of new products offset growth in established products.
- Debt Restructuring: Total debt increased to $1.299 billion. In December 2025, the company issued $108 million in convertible bonds (6.875% coupon) and entered a $100 million senior term loan (12.50% fixed rate). In June 2025, the existing Secured Loan Facility was amended to consolidate tranches and reduce the interest rate to SOFR + 6.0%.
- Regulatory Setbacks: In Q4 2025, the FDA issued Complete Response Letters (CRLs) for BLAs for AVT03, AVT05, and AVT06. The CRLs cited deficiencies identified during a pre-license inspection of the Reykjavik facility. The company has initiated a remediation plan.
- Acquisitions: Completed the acquisition of Ivers-Lee Group (packaging/supply chain) in July 2025, resulting in a bargain purchase gain of $8.0 million. Acquired Xbrane Biopharma's R&D operations in June 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue funding operations through existing cash, projected milestone collections, and product revenues. The company anticipates continued expenses for R&D, regulatory submissions, and commercialization. No specific quantitative guidance for 2026 revenue or earnings was provided in the text.
- Key Risks:
- Regulatory Approval: U.S. market entry for AVT03, AVT05, and AVT06 is delayed pending resolution of FDA facility deficiencies. Failure to resolve these could materially impact the business.
- Liquidity and Debt: The company has substantial indebtedness ($1.3 billion) with significant near-term refinancing needs. The December 2025 Senior Term Loan requires a full bullet repayment in December 2027. Failure to generate sufficient cash flow could lead to default or forced asset sales.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting (ICFR) as of December 31, 2025, related to control environment, segregation of duties, and deferred tax asset processes. The auditor issued an adverse opinion on ICFR.
- Competition and Pricing: Intense competition in biosimilar markets and potential pricing pressures from the U.S. Inflation Reduction Act (IRA) and global tenders.
Investor Verification Checklist
- FDA Remediation Status: Verify the timeline and progress of resolving the manufacturing deficiencies at the Reykjavik facility to secure U.S. approval for AVT03, AVT05, and AVT06.
- Debt Service Capacity: Assess the company's ability to service $1.3 billion in debt, specifically the $100 million bullet repayment due in December 2027 and the interest burden of the new 12.5% term loan.
- Internal Control Remediation: Monitor the progress of remediation efforts for the material weaknesses in ICFR to ensure future financial reporting reliability.
- Commercial Launch Execution: Track the actual launch dates and initial sales performance of AVT03, AVT05, and AVT06 in the EEA, UK, and Japan, and the subsequent U.S. launch timeline.
- Deferred Tax Assets: Review the assumptions used to recognize $181.4 million in deferred tax assets, given the recent derecognition of $130 million due to revised profitability forecasts.